CombiMatrix Names Karen Warner, RN, Vice President of Reimbursement
January 20 2015 - 8:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for pre- and
postnatal developmental disorders, today announced the appointment
of Karen Warner, RN, as Vice President of Payer Access and
Reimbursement. Ms. Warner joined on January 19, 2015 and will be
responsible for managed care, payer access, and reimbursement.
"Karen joins CombiMatrix at a very exciting time for the company
with the recent additions of new products to our prenatal testing
portfolio and our continued sales growth," said Mark McDonough,
President and Chief Executive Officer of CombiMatrix. "Karen's
expertise in payer relations and reimbursement will be a critical
asset as we work to expand coverage of our service offerings across
payer types and geographies nationwide."
Ms. Warner has more than 30 years of experience in the
healthcare industry. She joins CombiMatrix from Bako Integrated
Physician Solutions where she served as Director of Payer Relations
and was responsible for national market access for all payers,
including Medicare, Medicaid, commercial and other government
program and private institution payers. Within 12 months at Bako,
she secured direct multi-year national agreements at preferred
pricing with six large national payers and 27 key regional/state
Blues plans. Prior to Bako, Ms. Warner was president of Touch Point
Consulting, a payer relations consulting company in molecular
diagnostics, genetics and personalized medicine. Ms. Warner has
previously held various positions in payer relations and
reimbursement at Genoptix Medical Laboratories, Alkermes and
Sanofi-Synthelabo. Ms. Warner is a Registered Nurse and holds a BSN
from the University of Bridgeport.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of abnormalities of genes at the DNA
level beyond what can be identified through traditional
technologies. The Company performs genetic testing utilizing
microarray, FISH, PCR and G-Band chromosome analyses. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words. These
forward-looking statements are not guarantees of future results and
are subject to risks, uncertainties and assumptions that could
cause our actual results to differ materially and adversely from
those expressed in any forward-looking statement. The risks
and uncertainties referred to above include, but are not limited
to: market acceptance of CMA as a preferred method over
karyotyping; the rate of transition to CMA from karyotyping; our
ability to successfully expand the base of our customers and
strategic partners, add to the menu of our diagnostic tests in both
of our primary markets, develop and introduce new tests and related
reports, optimize the reimbursements received for our testing
services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to
successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer
rosters in both developmental medicine and oncology; our ability to
attract and retain a qualified sales force; rapid technological
change in our markets; changes in demand for our future products;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further
information on potential factors that could affect our financial
results is included in our Annual Report on Form 10-K, Quarterly
Reports of Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or
update publicly any forward-looking statements for any reason,
except as required by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
Robert Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com
Media Contact:
David Schull or Lena Evans
Russo Partners LLC
(212) 845-4271
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2023 to Apr 2024